
-
IGM Biosciences NasdaqGS:IGMS IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Location: 325 East Middlefield Road, Mountain View, CA, 94043, United States | Website: https://igmbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-37.22M
Cash
152.1M
Avg Qtr Burn
-35.77M
Short % of Float
7.68%
Insider Ownership
37.57%
Institutional Own.
47.29%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IGM-7354 (IL-15 x PD-L1) Details Solid tumor/s, Cancer, Hematologic malignancies | Phase 1 Update | |
Aplitabart (IGM-8444) + venetoclax & azacytidine Details Acute myeloid leukemia | Phase 1 Update | |
Aplitabart (IGM-8444) + birinapant Details Hematologic malignancies, Solid tumor/s | Phase 1 Update | |
Aplitabart (IGM-8444) (DR5 agonist) + FOLFIRI +/- bevacizumab Details Cancer, Solid tumor/s, Colorectal cancer | Phase 1 Update | |
Imvotamab (IGM-2323) (CD20 x CD3) Details Cancer, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma | Failed Discontinued | |
Imvotamab (IGM-2323) (CD20 x CD3) Details Systemic lupus erythematosus, Autoimmune disease | Failed Discontinued | |
Imvotamab (IGM-2323) (CD20 x CD3) Details Autoimmune disease, Rheumatoid arthritis | Failed Discontinued | |
Imvotamab (IGM-2323) (CD20 x CD3) Details Idiopathic inflammatory myopathy / myositis | Failed Discontinued | |
IGM-2644 (CD38 x CD3) Details Multiple myeloma | Failed Discontinued | |
IGM-6268 Details Solid tumor/s, Cancer | Failed Discontinued |